Sofosbuvir (Sovaldi) for the treatment of hepatitis C

References

• Hope VD, Eramova I, Capurro D, Donoghoe M C. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014;142(2):270-86
   PubMed Web of Science ®Google Scholar
• Kharyriyyah MH, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Alcorn T. Mongolia’s struggle with liver cancer. Lancet 2011;377(9772):1139-40
   PubMed Web of Science ®Google Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis c virus infection among persons born during 1945–1965. MMWR Recomm Rep 2012;61(RR-4):1-32
   PubMedGoogle Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Ann Intern Med;2012(157):817-22
   Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis c virus infection in the United States,1999 through 2002. Ann Intern Med 2006;144(10):705-14
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. The National Academies Press; Washington DC, USA: 2010
   Google Scholar
• Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA. Liver Int 2011;31(8):1090-101
   PubMed Web of Science ®Google Scholar
• North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013;35(2):122-8
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138(2):513-21. 521.e1-6
   PubMed Web of Science ®Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
   PubMedGoogle Scholar
• Lee MH, Yang HI; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206(4):469-77
   PubMed Web of Science ®Google Scholar
• Razavi H, ElKhoury AC, Elbasha E, Chronic Hepatitis C. Virus (HCV) disease burden and cost in the United States. Hepatology 2013;57(6):2164-70
   PubMed Web of Science ®Google Scholar
• Biggins SW, Bambha KM, Terrault MA, et al. Projected future increase in aging hepatitis C virus liver transplant candidates; a potential effect of hepatocellular carcinoma. Liver Transpl 2012;18(12):1471-8
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9(4):331-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144(7):1450-5. e2
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA 2012;308(24):2584-93
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60(3):530-7
   PubMed Web of Science ®Google Scholar
• Moyer VA; on behalf of the USPSTF. Updated guidelines for hepatitis B and C; treatment guidelines for hepatitis B. Ann Intern Med 2013. [Epub ahead of print]
   Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24. Erratum in N Engl J Med 2011;365(16):1551
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 investigators. boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 investigators. boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Vierling JM, Davis M, Flamm S, et al. Boceprevir for chronic hcv genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol 2014;60(4):748-562013
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011;140(3):746-54
   PubMedGoogle Scholar
• Ferenci P, Dusheiko G. Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis. Gut 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59(3):434-41
   PubMed Web of Science ®Google Scholar
• Schmidt-Martin D, Houlihan D, McCormick A. From the CUPIC study: great times are not coming (?). J Hepatol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rockstroh JK. Summary from EASL 2013 for hepatitis C - new HCV DAAs on their way soon: what do the phase III studies tell us? Available from: http://natap.org/2013/EASL/EASL_106.htm [Last accessed on March 2014]
   Google Scholar
• Olysio US full prescribing information
   Google Scholar
• EASL recommendations on treatment of hepatitis C 2014. Available from: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf [Last accessed on 5 November 2014]
   Google Scholar
• Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146(2):430-41.e6
   PubMed Web of Science ®Google Scholar
• Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014;49(1):138-47
   PubMed Web of Science ®Google Scholar
• Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58(6):1918-29
   PubMed Web of Science ®Google Scholar
• Sovaldi US full prescribing information
   Google Scholar
• Gilead Sciences, Inc. Press release European Commission grants marketing authorization for gilead’s sovaldi® (sofosbuvir) for the treatment of chronic hepatitis C infection. Available from: http://www.gilead.com/news/press-releases/2014/1/european-commission-grants-marketing-authorization-for-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c-infection [Last accessed on 5 November 2014]
   Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Rafiq N, Stepanova M, Lam B, et al. Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. Ann Hepatol 2013;13(1):60-4
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Lewden C, Morlat P, et al. Mortality 2000 study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42(6):799-805
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Press release Gilead’s Sovaldi® demonstrates efficacy and safety among chronic hepatitis C patients with advanced liver disease. Available from: http://www.gilead.com/news/press-releases/2014/4/gileads-sovaldi-demonstrates-efficacy-and-safety-among-chronic-hepatitis-c-patients-with-advanced-liver-disease [Last accessed on 5 November 2014]
   Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60(4):741-7
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Press release Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of Sofosbuvir and Ledipasvir for genotype 1 hepatitis c patients, 2013. Available from: http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients [Last accessed on 13 March 2014]
   Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. The ION-3 investigators. ledipasvir and sofosbuvir for 8 or 12 weeks for chronic hcv without cirrhosis. N Engl J Med 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. ION-2 investigators. ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. The ION-1 investigators. ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and bms-791325 in treatment-naive patients with hcv genotype 1 infection. Gastroenterology 2014;146(2):420-9
   PubMed Web of Science ®Google Scholar
• AbbVie. Press release ABBVIE completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis C genotype 1. Available from: http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1 [Last accessed on 13 March 2014]
   Google Scholar
• Afdhal NH, Zeuzem S, Schooley RT, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20(11):745-60
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
   PubMed Web of Science ®Google Scholar
• A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (COSMOS). Available from: http://clinicaltrials.gov/ct2/show/NCT01466790
   Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21
   PubMed Web of Science ®Google Scholar